United States Biotechnology & Medical Research

Bambusa Therapeutics Inc (BBTX)

Bambusa Therapeutics Inc witnessed two significant insider trading transactions on November 2, 2026. Salvia Investment GmbH and Jeggle Helmut Wolfgang each purchased shares valued at 6 million dollars, totaling 12 million dollars in net buying. These acquisitions represent approximately 0.21 percent of the float, occurring while the stock trades at its fifty-two-week peak.
Ticker: BBTX
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Bambusa Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
385.55
Quantity 56,328 +38.4%
Value US$1,329,365
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
73.31
Quantity 32,480 +48.5%
Value US$1,631,014
Salvia Investment GmbH Large shareholder
Transaction date
Purchase
Price
134.57
Quantity 53,261 +10.4%
Value US$4,865,715
Jeggle Helmut Wolfgang Non-Executive Director Large shareholder
Transaction date
Purchase
Price
16.00
Quantity 1,000 +4.2%
Value US$100,000
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
14.92
Quantity 1,000 +139.0%
Value US$100,000
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
14.23
Quantity 1,000 New position
Value US$100,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-11-03 2026-11-02 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
56,328 +38.4%
385.55
US$1,329,365 		56,328 +38.4% 385.55 US$1,329,365
2026-11-03 2026-11-02 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
32,480 +48.5%
73.31
US$1,631,014 		32,480 +48.5% 73.31 US$1,631,014
2026-11-02 2026-11-02 B Purchase
Salvia Investment GmbH
Large shareholder
53,261 +10.4%
134.57
US$4,865,715 		53,261 +10.4% 134.57 US$4,865,715
2026-11-02 2026-11-02 B Purchase
Jeggle Helmut Wolfgang
Non-Executive Director Large shareholder
1,000 +4.2%
16.00
US$100,000 		1,000 +4.2% 16.00 US$100,000
2026-11-03 2026-10-30 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
1,000 +139.0%
14.92
US$100,000 		1,000 +139.0% 14.92 US$100,000
2026-11-03 2026-10-30 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
1,000 New position
14.23
US$100,000 		1,000 New position 14.23 US$100,000
Explore more

More insider trading research around Bambusa Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America